Shanghai Fosun Pharmaceutical (Group) Co (HK:2196) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Shanghai Fosun Pharmaceutical has received approval from the National Medical Products Administration for its new drug, Botulinum Toxin Type A, aimed at treating cervical dystonia in adults. This development follows their exclusive licensing agreement with Revance Therapeutics to import, use, and commercialize the drug in China, Hong Kong, and Macau. This approval marks a significant milestone for Fosun Pharma in expanding its portfolio in the pharmaceutical market.
For further insights into HK:2196 stock, check out TipRanks’ Stock Analysis page.
